Antiparkinsonian mechanism of electroconvulsive therapy in MPTP-lesioned non-human primates

Neurodegenerative Diseases

Volumn 9, Issue 3, 2012, Pages 128-138

  Landau, Anne M ^a,b   Clark, Campbell ^b   Jivan, Salma ^c   Doudet, Doris J ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c TRIUMF   (Canada)

Author keywords

1 Methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Dopamine; Dopamine 1 receptor; Dopamine 2 receptor; Dopamine transporter; Electroconvulsive therapy; Non human primate; Parkinson's disease; Positron emission tomography; Vesicular monoamine transporter 2

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; TRACER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; ELECTROCONVULSIVE THERAPY; MALE; NEUROIMAGING; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING; RHESUS MONKEY; THERAPY EFFECT;

ANIMALS; CORPUS STRIATUM; DOPAMINE; ELECTROCONVULSIVE THERAPY; MACACA MULATTA; MALE; MPTP POISONING;

EID: 84858996951     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000334497     Document Type: Article

References (71)

1. Brown R, Jahanshahi M: Depression in Parkinsons disease: a psychosocial viewpoint. Adv Neurol 1995; 65: 61-84.
2. Tandberg E, Larsen JP, Aarsland D, Cummings JL: The occurrence of depression in Parkinsons disease. A community-based study. Arch Neurol 1996; 53: 175-179. (Pubitemid 26055265)
3. Slaughter JR, Slaughter KA, Nichols D, Holmes SE, Martens MP: Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinsons disease. J Neuropsychiatry Clin Neurosci 2001; 13: 187-196. (Pubitemid 32499670)
4. Andersen K, Balldin J, Gottfries CG, Granerus AK, Modigh K, Svennerholm L, Wallin A: A double-blind evaluation of electroconvulsive therapy in Parkinsons disease with on-off phenomena. Acta Neurol Scand 1987; 76: 191-199. (Pubitemid 17144130)
5. Faber R, Trimble MR: Electroconvulsive therapy in Parkinsons disease and other movement disorders. Mov Disord 1991; 6: 293-303.
6. Fromm GH: Observations on the effect of electroshock treatment on patients with parkinsonism. Bull Tulane Univ Med Fac 1959; 18: 71-73.
7. Balldin J, Granerus AK, Lindstedt G, Modigh K, Walinder J: Predictors for improvement after electroconvulsive therapy in parkinsonian patients with on-off symptoms. J Neural Transm 1981; 52: 199-211. (Pubitemid 12228604)
8. Holcomb HH, Sternberg DE, Heninger GR: Effects of electroconvulsive therapy on mood, parkinsonism, and tardive dyskinesia in a depressed patient: ECT and dopamine systems. Biol Psychiatry 1983; 18: 865-873. (Pubitemid 13045333)
9. Douyon R, Serby M, Klutchko B, Rotrosen J: ECT and Parkinsons disease revisited: a naturalistic study. Am J Psychiatry 1989; 146: 1451-1455. (Pubitemid 19271384)
10. Zervas IM, Fink M: ECT for refractory Parkinsons disease. Convuls Ther 1991; 7: 222-223.
11. Pridmore S, Pollard C: Electroconvulsive therapy in Parkinsons disease: 30-month follow-up. J Neurol Neurosurg Psychiatry 1996; 60: 693.
12. Fernandez-Corcuera P, Aguilar S, Vicens V, Mora J, Benitez A, Garcia-Burillo A, Pomarol-Clotet E, McKenna P: ECT in a patient with Parkinsons disease and schizophrenia, with dopamine transporter visualisation using 123I-ioflupane SPET. J Neural Transm 2011; 118: 647-650.
13. Costain DW, Cowen PJ, Gelder MG, Grahame-Smith DG: Electroconvulsive therapy and the brain: evidence for increased dopamine-mediated responses. Lancet 1982; ii:400-404. (Pubitemid 12039834)
14. Zis AP, Yatham LN, Lam RW, Clark CM, Srisurapanont M, McGarvey K: Effect of stimulus intensity on prolactin and cortisol release induced by unilateral electroconvulsive therapy. Neuropsychopharmacology 1996; 15: 263-270. (Pubitemid 26285656)
15. Nomikos GG, Zis AP, Damsma G, Fibiger HC: Effects of chronic electroconvulsive shock on interstitial concentrations of dopamine in the nucleus accumbens. Psychopharmacology (Berl) 1991; 105: 230-238.
16. Zis AP, Nomikos GG, Brown EE, Damsma G, Fibiger HC: Neurochemical effects of electrically and chemically induced seizures: an in vivo microdialysis study in the rat hippocampus. Neuropsychopharmacology 1992; 7: 189-195.
17. McGarvey KA, Zis AP, Brown EE, Nomikos GG, Fibiger HC: ECS-induced dopamine release: effects of electrode placement, anticonvulsant treatment, and stimulus intensity. Biol Psychiatry 1993; 34: 152-157. (Pubitemid 23257741)
18. Strome EM, Zis AP, Doudet DJ: Electroconvulsive shock enhances striatal dopamine D 1 and D 3 receptor binding and improves motor performance in 6-OHDA-lesioned rats. J Psychiatry Neurosci 2007; 32: 193-202. (Pubitemid 46903860)
19. Green AR, Heal DJ, Grahame-Smith DG: Further observations on the effect of repeated electroconvulsive shock on the behavioural responses of rats produced by increases in the functional activity of brain 5-hydroxytryptamine and dopamine. Psychopharmacology (Berl) 1977; 52: 195-200. (Pubitemid 8090212)
20. Fochtmann LJ: Animal studies of electroconvulsive therapy: foundations for future research. Psychopharmacol Bull 1994; 30: 321-444.
21. Rosa DV, Souza RP, Souza BR, Motta BS, Caetano F, Jornada LK, Feier G, Gomez MV, Quevedo J, Romano-Silva MA: DARPP-32 expression in rat brain after electroconvulsive stimulation. Brain Res 2007; 1179: 35-41. (Pubitemid 350001354)
22. Bergstrom DA, Kellar KJ: Effect of electroconvulsive shock on monoaminergic receptor binding sites in rat brain. Nature 1979; 278: 464-466. (Pubitemid 9133276)
23. Fochtmann LJ, Cruciani R, Aiso M, Potter WZ: Chronic electroconvulsive shock increases D-1 receptor binding in rat substantia nigra. Eur J Pharmacol 1989; 167: 305-306. (Pubitemid 19215483)
24. Barkai AI, Durkin M, Nelson HD: Localized alterations of dopamine receptor binding in rat brain by repeated electroconvulsive shock: an autoradiographic study. Brain Res 1990; 529: 208-213. (Pubitemid 20326858)
25. Landau AM, Chakravarty MM, Clark CM, Zis AP, Doudet DJ: Electroconvulsive therapy alters dopamine signaling in the striatum of non-human primates. Neuropsychopharmacology 2011; 36: 511-518.
26. Yatham LN, Liddle PF, Lam RW, Zis AP, Stoessl AJ, Sossi V, Adam MJ, Ruth TJ: Effect of electroconvulsive therapy on brain 5-HT 2 receptors in major depression. Br J Psychiatry 2010; 196: 474-479.
27. Strome EM, Clark CM, Zis AP, Doudet DJ: Electroconvulsive shock decreases binding to 5-HT 2 receptors in nonhuman primates: An in vivo positron emission tomography study with [ 18 F]setoperone. Biol Psychiatry 2005; 57: 1004-1010. (Pubitemid 40603083)
28. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ: A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine. Proc Natl Acad Sci USA 1983; 80: 4546-4550. (Pubitemid 13077876)
29. Langston JW, Forno LS, Rebert CS, Irwin I: Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 1984; 292: 390-394. (Pubitemid 14190114)
30. Doudet D, Gross C, Lebrun-Grandie P, Bioulac B: MPTP primate model of Parkinsons disease: a mechanographic and electromyographic study. Brain Res 1985; 335: 194-199. (Pubitemid 15035377)
31. Doudet DJ, Chan GL, Holden JE, McGeer EG, Aigner TA, Wyatt RJ, Ruth TJ: 6-[ 18 F]fluoro-L -DOPA pet studies of the turnover of dopamine in MPTP-induced parkinsonism in monkeys. Synapse 1998; 29: 225-232. (Pubitemid 28267931)
32. Doudet DJ, Rosa-Neto P, Munk OL, Ruth TJ, Jivan S, Cumming P: Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multitracer PET study. Neuroimage 2006; 30: 26-35. (Pubitemid 43243194)
33. Doudet DJ, Holden JE, Jivan S, McGeer E, Wyatt RJ: In vivo PET studies of the dopamine D 2 receptors in rhesus monkeys with long-term MPTP-induced parkinsonism. Synapse 2000; 38: 105-113.
34. Doudet DJ, Jivan S, Ruth TJ, Wyatt RJ: In vivo PET studies of the dopamine D 1 receptors in rhesus monkeys with long-term MPTP-induced parkinsonism. Synapse 2002; 44: 111-115.
35. Zhang Z, Andersen A, Smith C, Grondin R, Gerhardt G, Gash D: Motor slowing and parkinsonian signs in aging rhesus monkeys mirror human aging. J Gerontol A Biol Sci Med Sci 2000; 55:B473-B480. (Pubitemid 32010283)
36. Emborg ME, Ma SY, Mufson EJ, Levey AI, Taylor MD, Brown WD, Holden JE, Kordower JH: Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 1998; 401: 253-265. (Pubitemid 28481965)
37. Kordower JH, Liu YT, Winn SR, Emerich DF: Encapsulated PC12 cell transplants into hemiparkinsonian monkeys: a behavioral, neuroanatomical and neurochemical analysis. Cell Transplant 1995; 4: 155-171.
38. Kurlan R, Kim MH, Gash DM: Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Mov Disord 1991; 6: 111-118.
39. Doudet DJ, Cornfeldt M, Honey C, Schweikert AW, Allen RC: PET imaging of implanted human retinal pigment epithelial cells in the MPTP-induced primate model of Parkinsons disease (PD). Exp Neurol 2004; 89: 361-368. (Pubitemid 39221828)
40. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL: Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996; 16: 834-840. (Pubitemid 26292051)
41. Popeo D, Kellner CH: ECT for Parkinsons disease. Med Hypotheses 2009; 73: 468-469.
42. Rasmussen K, Abrams R: Treatment of Parkinsons disease with electroconvulsive therapy. Psychiatr Clin North Am 1991; 14: 925-933.
43. Kellner CH, Beale MD, Pritchett JT, Bernstein HJ, Burns CM: Electroconvulsive-therapy and Parkinsons-disease -the case for further study. Psychopharmacol Bull 1994; 30: 495-500.
44. Chen MK, Kuwabara H, Zhou Y, Adams RJ, Brasic JR, McGlothan JL, Verina T, Burton NC, Alexander M, Kumar A, Wong DF, Guilarte TR: VMAT2 and dopamine neuron loss in a primate model of Parkinsons disease. J Neurochem 2008; 105: 78-90. (Pubitemid 351441627)
45. Kilbourn MR, Frey KA, Vander Borght T, Sherman PS: Effects of dopaminergic drug treatments on in vivo radioligand binding to brain vesicular monoamine transporters. Nucl Med Biol 1996; 23: 467-471. (Pubitemid 26233217)
46. Kilbourn MR, Butch ER, Desmond T, Sherman P, Harris PE, Frey KA: In vivo [11C]dihydrotetrabenazine binding in rat striatum: sensitivity to dopamine concentrations. Nucl Med Biol 2010; 37: 3-8.
47. Tong J, Wilson AA, Boileau I, Houle S, Kish SJ: Dopamine modulating drugs influence striatal (+)-[ 11 C]DTBZ binding in rats: VMAT2 binding is sensitive to changes in vesicular dopamine concentration. Synapse 2008; 62: 873-876.
48. Sossi V, Dinelle K, Schulzer M, Mak E, Doudet DJ, de la Fuente-Fernandez R: Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release. Eur J Nucl Med Mol Imaging 2010; 37: 2364-2370.
49. Nowak G, Zak J: Repeated electroconvulsive shock (ECS) enhances striatal D-1 dopamine receptor turnover in rats. Eur J Pharmacol 1989; 167: 307-308. (Pubitemid 19215484)
50. Sershen H, Wolinsky T, Douyon R, Hashim A, Wiener HL, Lajtha A, Coons EE, Serby M: The effects of electroconvulsive shock on dopamine-and dopamine-2 receptor ligand binding activity in MPTP-treated mice. J Neuropsychiatry Clin Neurosci 1991; 3: 58-63.
51. Smith S, Lindefors N, Hurd Y, Sharp T: Electroconvulsive shock increases dopamine D 1 and D 2 receptor mRNA in the nucleus accumbens of the rat. Psychopharmacology (Berl) 1995; 120: 333-340.
52. Inoue O, Tsukada H, Yonezawa H, Suhara T, Langstrom B: Reserpine-induced reduction of in vivo binding of SCH 23390 and Nmethylspiperone and its reversal by D -amphetamine. Eur J Pharmacol 1991; 197: 143-149.
53. Marshall JF, Navarrete R, Joyce JN: Decreased striatal D 1 binding density following mesotelencephalic 6-hydroxydopamine injections: an autoradiographic analysis. Brain Res 1989; 493: 247-257. (Pubitemid 19183755)
54. Joyce JN: Differential response of striatal dopamine and muscarinic cholinergic receptor subtypes to the loss of dopamine. II. Effects of 6-hydroxydopamine or colchicine microinjections into the VTA or reserpine treatment. Exp Neurol 1991; 113: 277-290.
55. Kobayashi K, Inoue O: An increase in the in vivo binding of [ 3 H]SCH 23390 induced by MK-801 in the mouse striatum. Neuropharmacology 1993; 32: 341-348. (Pubitemid 23122633)
56. Lammers CH, Diaz J, Schwartz JC, Sokoloff P: Selective increase of dopamine D 3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol Psychiatry 2000; 5: 378-388. (Pubitemid 30455951)
57. Gordon I, Weizman R, Rehavi M: Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol 1996; 298: 27-30. (Pubitemid 26071176)
58. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, de la Fuente-Fernandez R, Calne DB, Stoessl AJ: In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinsons disease. Ann Neurol 2000; 47: 493-503. (Pubitemid 30194606)
59. Innis R, Baldwin R, Sybirska E, Zea Y, Laruelle M, al-Tikriti M, Charney D, Zoghbi S, Smith E, Wisniewski G, et al: Single photon emission computed tomography imaging of monoamine reuptake sites in primate brain with [ 123 I]CIT. Eur J Pharmacol 1991; 200: 369-370.
60. Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, Ravert HT, Dannals RF: Positron emission tomographic imaging of the dopamine transporter with 11 C-WIN 35,428 reveals marked declines in mild Parkinsons disease. Ann Neurol 1993; 34: 423-431. (Pubitemid 23259619)
61. Guttman M, Burkholder J, Kish SJ, Hussey D, Wilson A, DaSilva J, Houle S: [ 11 C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinsons disease: implications for the symptomatic threshold. Neurology 1997; 48: 1578-1583.
62. Seibyl JP, Marek KL, Quinlan D, Sheff K, Zoghbi S, Zea-Ponce Y, Baldwin RM, Fussell B, Smith EO, Charney DS, van Dyck C, et al: Decreased single-photon emission computed tomographic [123I]-CIT striatal uptake correlates with symptom severity in Parkinsons disease. Ann Neurol 1995; 38: 589-598.
63. Nagai Y, Obayashi S, Ando K, Inaji M, Maeda J, Okauchi T, Ito H, Suhara T: Progressive changes of pre-and post-synaptic dopaminergic biomarkers in conscious MPTP-treated cynomolgus monkeys measured by positron emission tomography. Synapse 2007; 61: 809-819. (Pubitemid 47328799)
64. Fall PA, Ekberg S, Granerus AK, Granerus G: ECT in Parkinsons disease-dopamine transporter visualised by [123I]-CIT SPECT. J Neural Transm 2000; 107: 997-1008.
65. Machado-Vieira R, Salvadore G, DiazGranados N, Zarate CA Jr: Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 2009; 123: 143-150.
66. Strome EM, Zis AP, Doudet DJ: Electroconvulsive shock enhances striatal D 1 and D 3 receptor binding and improves motor performance in 6-OHDA-lesioned rats. J Psychiatry Neurosci 2007; 32: 193-202. (Pubitemid 46903860)
67. Faber R, Trimble MR: Electroconvulsive therapy in Parkinsons disease and other movement disorders. Mov Disord 1991; 6: 293-303.
68. Andersen K, Balldin J, Gottfries CG, Granerus AK, Modigh K, Svennerholm L, Wallin A: A double-blind evaluation of electroconvulsive therapy in Parkinsons disease with on-off phenomena. Acta Neurol Scand 1987; 76: 191-199. (Pubitemid 17144130)
69. Chou KL, Hurtig HI, Jaggi JL, Baltuch GH, Pelchat RJ, Weintraub D: Electroconvulsive therapy for depression in a Parkinsons disease patient with bilateral subthalamic nucleus deep brain stimulators. Parkinsonism Relat Disord 2005; 11: 403-406. (Pubitemid 41317810)
70. Nasr S, Murillo A, Katariwala N, Mothkur V, Wendt B: Case report of electroconvulsive therapy in a patient with Parkinson disease concomitant with deep brain stimulation. J ECT 2011; 27: 89-90.
71. Ueda S, Koyama K, Okubo Y: Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT 2010; 26: 111-115.